Adial Pharmaceuticals reports Q3 net loss $1.8M vs $2.2M last year

Cash and cash equivalents were $4.6 million as of September 30, 2025, compared to $5.9 million as of June 30, 2025. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the second quarter of 2026 based on currently committed development plans. Cary Claiborne, CEO of Adial Pharmaceuticals (ADIL), commented, “We continue to achieve meaningful milestones on our path toward U.S. Food and Drug Administration approval and eventual commercialization of AD04, our lead investigational drug, a serotonin-3 receptor antagonist being developed for the treatment of Alcohol Use Disorder. A key highlight of our recent progress was the successful End of Phase 2 meeting with the FDA, where we received valuable guidance on critical elements of our planned adaptive Phase 3 study design – including the target population, clinical endpoints, inclusion and exclusion criteria, dosing regimen, and validation of both biomarker-positive and biomarker-negative groups.”